The research firm Twist Bioscience has secured $ 70 m from its initial public offering ( IPO ) , selling five million shares at $ 14 each . Here’s more on the origins of Twist and its approach to DNA synthesis. The company has developed a proprietary technology that manufactures synthetic DNA by “ writing ” it on a silicon chip , which it claims makes DNA synthesis scalable and less expensive than using traditional methods . Twist plans to use the investment capital to fund new equipment and expand research and development , as well as expanding its sales and marketing operations , and establishing a presence in China .
The research firm Twist Bioscience has secured $ 70 m from its initial public offering ( IPO ) , selling five million shares at $ 14 each . The company has developed a proprietary technology that manufactures synthetic DNA by “ writing ” it on a silicon chip , which it claims makes DNA synthesis scalable and less expensive than using traditional methods . Twist plans to use the investment capital to fund new equipment and expand research and development , as well as expanding its sales and marketing operations , and establishing a presence in China .